Italia markets open in 8 hours 23 minutes

MRUS Jul 2024 60.000 call

OPR - OPR Prezzo differito. Valuta in USD.
Aggiungi a watchlist
0,35000,0000 (0,00%)
In data: 02:08PM EDT. Mercato aperto.
Schermo intero
Chiusura precedente0,3500
Aperto0,5500
Denaro0,2000
Domanda0,6500
Prezzo d'esercizio60,00
Scadenza2024-07-19
Min-Max giorno0,3500 - 0,5500
Contratto - Min-MaxN/D
Volume14
Open InterestN/D
  • GlobeNewswire

    Merus Announces Business Update Conference Call

    Zeno interim clinical data continues to show robust efficacy in NRG1+ NSCLC and PDAC: Sufficient clinical data expected in 1H24 to support potential BLA submissions Petosemtamab 2L+ HNSCC phase 3 trial design supported by INTERLINK-1 control armClinical data update on petosemtamab monotherapy in 2L+ HNSCC planned 2024MCLA-129 abstracts accepted at ESMO AsiaInvestor call on Monday, October 16 at 7:30 a.m. ET UTRECHT, The Netherlands and CAMBRIDGE, Mass., Oct. 15, 2023 (GLOBE NEWSWIRE) -- Merus N.

  • GlobeNewswire

    Merus Announces Abstracts Accepted for Presentation at the ESMO Asia Congress 2023

    Mini Oral: MCLA-129 in combination with osimertinib in treatment naïve, and after progression on osimertinib, non-small cell lung cancer Poster: MCLA-129 in previously treated head & neck squamous cell carcinoma UTRECHT, The Netherlands and CAMBRIDGE, Mass., Oct. 06, 2023 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the acc

  • GlobeNewswire

    Merus to Participate in Upcoming Investor Conferences

    UTRECHT, The Netherlands and CAMBRIDGE, Mass., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will participate in the following investor conferences: Citi's 2023 18th Annual BioPharma Conference (fireside chat): Thursday, September 7 at 2:40-3:25 p.m. ETMorgan Stanley 21st A